249420.KS
Ildong Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 15,100.00
−8.43%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 582.3B | 566.9B | 614.9B | 600.8B | 637.7B |
| Cost of Revenue | 358.8B | 352.2B | 381.5B | 393.2B | 401.4B |
| Gross Profit | 223.6B | 214.8B | 233.5B | 207.5B | 236.3B |
| Operating Expenses | |||||
| R&D Expense | 27.6B | 35.6B | 46.3B | 95.0B | 109.9B |
| SG&A Expense | 61.6B | 81.2B | 92.8B | 82.3B | 107.0B |
| General & Admin Expense | 13.7B | 14.1B | 11.2B | 11.3B | 17.1B |
| Selling & Marketing Expense | 47.9B | 67.0B | 81.6B | 71.0B | 89.9B |
| Other Expenses | 112.6B | 80.7B | 81.3B | 83.6B | 92.8B |
| Total Operating Expenses | 201.8B | 197.4B | 220.3B | 261.0B | 309.7B |
| Cost and Expenses | 557.0B | 547.5B | 601.8B | 654.2B | 711.0B |
| Operating Income (EBIT) | 25.5B | 17.3B | 13.1B | (53.4B) | (73.3B) |
| Non-Operating | |||||
| Interest Income | 616.2M | 942.1M | 1.1B | 1.1B | 1.6B |
| Interest Expense | 8.0B | 12.2B | 18.1B | 14.7B | 9.8B |
| Net Interest Income | (7.4B) | (11.2B) | (16.9B) | (13.6B) | (8.2B) |
| Other Non-Op Income/Expense | 21.7B | 12.3B | (23.8B) | (40.9B) | (46.3B) |
| Non-Operating Income (excl Interest) | (26.0B) | — | 3.8B | 26.1B | 36.6B |
| EBT (Pre-Tax Income) | 47.1B | 31.8B | (10.7B) | (94.3B) | (119.8B) |
| Income Tax Expense | 7.5B | 8.1B | 1.7B | (13.3B) | 22.3B |
| Bottom Line | |||||
| Net Income | 43.6B | 27.7B | (4.6B) | (78.9B) | (142.2B) |
| Earnings from Cont. Ops | 39.6B | 23.7B | (12.4B) | (81.0B) | (142.2B) |
| Earnings from Discont. Ops | — | — | — | — | 535.5K |
| Bottom Line Net Income | 47.2B | 27.7B | (4.6B) | (78.9B) | (141.6B) |
| Per Share | |||||
| Basic EPS | ₩1,638 | ₩942 | (₩164) | (₩2,920) | (₩5,397) |
| Diluted EPS | ₩1,670 | ₩937 | (₩164) | (₩2,920) | (₩5,397) |
| Revenue Per Share | ₩28,722 | ₩18,876 | ₩22,016 | ₩22,226 | ₩24,207 |
| Shares | |||||
| Basic Shares Outstanding | 20.3M | 30.0M | 27.9M | 27.0M | 26.3M |
| Diluted Shares Outstanding | 20.3M | 30.0M | 27.9M | 27.0M | 26.3M |
| Profitability Metrics | |||||
| EBITDA | (5.5B) | 39.9B | 33.6B | (51.2B) | (80.5B) |
| D&A | 22.1B | 22.6B | 25.9B | 28.3B | 29.5B |
| EBIT | (27.6B) | 17.3B | 7.7B | (79.5B) | (110.0B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026